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Edited by Takashi GojoboriAbstract Disease-causing point mutations are assumed to act
predominantly through subsequent individual changes in the ami-
no acid sequence that impair the normal function of proteins.
However, point mutations can have a more dramatic eﬀect by
altering the splicing pattern of the gene. Here, we describe an ap-
proach to estimate the overall importance of splicing mutations.
This approach takes into account the complete set of genes
known to be involved in disease and suggest that, contrary to cur-
rent assumptions, many mutations causing disease may actually
be aﬀecting the splicing pattern of the genes.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Mathematical model1. Introduction
Point mutations are the most common cause of hereditary
disease and most of them (84% in the human gene mutation
database) are currently reported as missense or nonsense muta-
tions [1,2]. Most of the mutation analyses, however, are pri-
marily or exclusively performed at the genomic DNA level,
and the eﬀect of a mutation on the encoded mRNA and pro-
tein is predicted from the primary sequence alone. Only occa-
sionally the exact eﬀect of the mutation is experimentally
determined by analysis of the mRNA expression and splicing
patterns. In the few cases in which the eﬀect of mutations
has been experimentally veriﬁed at the DNA and RNA levels
[3,4] it has been found, however, that about 50% of the muta-
tions result in aberrant splicing. The question is whether these
genes are particularly sensitive to splicing mutations or
whether this represents an overall pattern of genes involved
in disease.
There are cases of other genes in which one or few mutations
outside the consensus splicing sites – in coding regions or in-
trons – have been studied in detail. Indeed, some have been re-
ported to disrupt splicing by creating a new splice site or by*Corresponding author.
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splicing enhancers [3–9]. Splicing mutations, thus, may play
a more important role than previously though in human hered-
itary disease. It could be that some or many of the point muta-
tions reported as changing one amino acid are in fact aﬀecting
the splicing pattern of the gene. In this regard, we discuss here
some existing data and explore mathematical modeling to
speculate on the importance of splicing mutations as causative
agents of disease.2. Importance of coding length in disease
A gene is catalogued as a disease gene when at least one
mutation in its sequence is identiﬁed and proved as the causa-
tive-mutation of a disease phenotype in one or several individ-
uals. The probability of a gene to be catalogued as a disease
gene should be proportional to the frequency of the disease
it cause, i.e., a gene that causes a frequent disease will be iden-
tiﬁed more easily than a gene that cause a rare disease. We
have previously shown that longer proteins are more likely
to be involved in disease [10] (Fig. 1(a)), probably because,
the longer the coding sequence of a gene, the more likely it is
to have disease-causing mutations, and thus, it is more likely
to be already in the databases as a disease gene. The length ef-
fect on the identiﬁcation of disease genes is made clear when
we classify the genes by the frequency of the disease they cause:
the average coding sequence length for genes causing common
disease (1:<10000) is 2270 bp, for rare disease (1:10–100000) is
1889 bp and for very rare disease (1:>100000) is 1768 bp (see
supplement for details). Table 1 shows the average coding
sequence length of genes involved in disease and those not
reported to be involved in disease (P-value 6 2.2 · 1016).3. Importance of splicing in disease
With the same reasoning, if splicing is an important mech-
anism of mutations, we would expect that the more splicing
junctions a gene has the more likely it is to be catalogued
as a disease gene. We have plotted the frequency of disease
genes as a function of the number of introns (Fig. 1(b)). It
is clear that the probability of a gene to be catalogued as a
disease gene increases with the number of introns. The aver-
age number of introns of the genes involved in disease is 12.4
while the average number of genes in the rest of human genes
is 9.2 (P-value < 2.2 · 1016) (Table 1). This could be theblished by Elsevier B.V. All rights reserved.
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Fig. 1. Probability for human genes to be disease genes as a function of the coding length (a) and number of splicing sites (b). In (a) and (b), we
report the estimated probability P for a gene to be classiﬁed as a disease gene computed for 8533 genes extracted from Swissprot (bullet). The vertical
bars correspond to plus/minus one standard deviation of the measurement errors. The horizontal bars represent the bins used to compute the
probabilities. They have been determined so that there are at least 300 genes per bin (due to this constraints the last bin overlaps with the previous
one). The grey line corresponds to the prediction of the model (Eq. (1)) with the parameter values given in the text. Note that the same set of
parameters allows to reproduce both the L and the I dependencies of probability P.
Table 1
Average values and Kolmogorov–Smirnov (KS) statistical analysis between two sets of genes
Values Average values in the set KS test
Disease genes Non-disease genes D P-value
Coding sequence length 2036 1595 16.3% <2.2 · 1016
Number of introns 12.4 9.2 14.3% <2.2 · 1016
Number of transcripts per gene 1.86 1.66 6.0% 8.3 · 104
Single-exon genes Split genes D P-value
Synonymous substitution rates 1.2 · 102 6.4 · 103 21.9% 1.8 · 108
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number of exons. However, the proportion of intronless
genes involved in disease (21/466, 4.5%) is signiﬁcantly smal-
ler than the proportion of one- and two-intron genes involved
in disease (51/479, 10.6% and 76/619, 12.2%, respectively)
although the corresponding gene coding length distributions
are similar (the average coding lengths for genes with one,
two and three exons are 943, 947 and 804 bp, respectively).
Although other factors may not be ruled out – for instance
that intronless and split genes may be involved in diﬀerent bio-
logical functions – this seems to suggest that the increase in the
frequency of disease genes with the number of exons is not
only mediated by the consequent increase in the length of
the protein, but it is rather a direct eﬀect of the increase in
the number of sequences involved in splicing – either splice
sites themselves or sequences involved in the regulation of
splicing.
In this regard, genes that have several alternative splicing
forms are expected to have more regulatory sequences of the
splicing process than genes not alternatively spliced, and these
sequences could be a target for mutations. Thus, if the hypoth-
esis that splicing regulatory sequences are an important target
of disease mutations was correct, we would expect those genes
with many alternative transcripts to be more often involved in
disease than those with only a few. The average number of
transcripts per gene (taking into account only multiple exons
genes) in the disease group is 1.86 and in the non-disease group
is 1.66 (P-value = 8.3 · 104) (Table 1).
The hypothesis that splicing regulatory sequences are an
important target of disease mutations implies that a fraction
larger than usually assumed of the point mutations occurring
in human genes – whether disease-causing or not – may be
aﬀecting their splicing pattern. Indeed, we have analysed syn-
onymous substitution rates between human and chimpanzee
genes in the data published by Clark et al. [11]. Substitution
rates are smaller in multiple exons genes (average 6.4 · 103)
than in intronless genes (average 1.2 · 102) (Table 1). Thus,
it appears that split genes have additional evolutionary con-
straints in their exonic sequences not directly related to protein
coding function. These constraints could reﬂect the widespread
distribution embedded in coding regions of sequence signals
involved in pre-mRNA splicing.
All these results seems to indicate that splicing is an impor-
tant factor in hereditary disease. However, the diﬀerences that
may apply to single-exon genes and split genes and the limited
information on alternatively spliced transcripts available im-
plies that a more sophisticated assessment of the importance
of splicing has to be performed. Some of these diﬀerences
are, for instance, that intronless genes are enriched for certain
functional categories, such as, histones or G protein coupled
receptors [12], they are more easily duplicated in the genome
through retrotransposition [13], it can be diﬃcult to accurately
discriminate functional genes from pseudogenes, lack of in-
trons might reﬂect more recent evolutionary origin of a gene
(i.e., it is not yet invaded by introns) which might correlate
with less essential functions, or the fact that multiexon genes
may be more susceptible to deletions or other rearrangements
because they are much larger. It is therefore important to eval-
uate this hypothesis further by taking into account informa-
tion on all human genes for which we have reliable gene
structure information.4. Probabilistic model to estimate the fraction of mutations
aﬀecting splicing
In order to assess the relative contribution of the two main
types of mutations causing disease (splicing and missense/non-
sense mutations) we have developed a probabilistic model
exploiting the complete set of human genes reported in Swiss-
Prot [14] and the complete set of known disease genes reported
by OMIM [15]. Our model takes into account the frequency
with which the complete set of genes have been identiﬁed as
disease genes as a function of their coding length or number
of introns.
In our model, we consider that the mutations leading to dis-
ease phenotype are of two independent types [2]. The ﬁrst type
aﬀects the coding sequence (missense/nonsense mutations or
codon mutations). The second type aﬀects sequences involved
in splicing (splicing mutations). We model the observed fre-
quency of disease genes as an exponential function of both
the coding length L and the number of introns I of the genes.
This functional form is obtained by assuming that mutations
occur at random (independently) along the DNA molecule.
Depending on the function of a gene the above mutations
can be lethal or have no phenotype, and thus, the gene will
not be classiﬁed as disease gene. Hence, we further assume
that only a proportion pmax of genes when mutated will be
identiﬁed as disease genes. More generally, pmax takes into ac-
count other factors independent on L and I that may aﬀect
the cataloguing of a gene as involved in disease. These
assumptions enable us to compute the probability of a gene
to be classiﬁed as a disease gene as a function of its coding
length and number of introns (see Methods in Supplementary
Material):
P ðgL;I 2 DÞ ¼ pmaxð1 expðklL kiIÞÞ; ð1Þ
where kl and ki are the eﬀective number of mutations per cod-
ing nucleotide and per intron, respectively, that result in the
identiﬁcation of a disease gene. Fitting this formula to the ob-
served frequency of disease genes computed as a function of L
and I, allow us to estimate the three parameters of the model
(kl, ki and pmax). Using this model, we can compute the number
of mutations of each type, and estimate the proportion of
mutations aﬀecting splicing over the total number of mutations
(see Supplementary material). We followed this procedure for
our data set of 8533 Human genes represented in SwissProt
[14] including 1306 disease genes [15]. We estimated
kl = (3.8 ± 0.7) · 104 per base pair, ki = (0.11 ± 0.02) per
splicing site and pmax = 0.185 ± 0.010.
When we ignored the genes with the most extreme coding
length or number of introns (333 genes with L P 4974 or
I P 33), the model properly reproduces the data
ðP v2 ¼ 0:07Þ. This is illustrated in Fig. 1, where the model pre-
diction (Eq. (1)) superposes convincingly with the observed fre-
quencies of disease genes. When the ﬁt was performed
considering only one dependency for the probability P (i.e.,
by forcing kl = 0 or ki = 0 in the model), ðP v2 Þ signiﬁcantly
drops from 0.07 to 0.002 for ki = 0 and 0.005 for kl = 0. In
other words, both kl and ki are necessary to reproduce the L
and I dependencies (Fig. 1). Note that 28% (93/333) of these
genes ignored are disease genes suggesting that extreme coding
length or number of introns may be a cause of an over-suscep-
tibility for disease mutations. From the estimated parameters,
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causing mutations according to the model is 0.62 ± 0.07.5. Discussion and conclusions
While other factors may not be ruled out – for instance, the
increased rate of gross lesion (i.e., mobile element insertions or
gross deletions) in very large genes or the eﬀect of splicing in
the expression levels [16,17] – it is the tendency of our results
more than the precise value of the estimate – which given the
simpliﬁcations of the model we cannot claim to be accurate
– that argues for splicing alterations to be an important mech-
anism of disease-causing mutations.
Compatible with our model predictions is the outcome of
several studies that have attempted to infer the eﬀect of a dis-
ease-causing mutation by analysing three-dimensional protein
structure [18]. Although there has been some relative success in
explaining the structural eﬀects of point mutations, in many
cases it is not possible to associate them either with an ac-
tive/binding site or a folding nucleus. This is in part due to
our limited detailed understanding of the factors aﬀecting pro-
tein structure, yet an intriguing possibility would be that a
number of these point mutations might actually aﬀect the
splicing patterns of the corresponding genes. They would
change substantially the amino acid sequence of the encoded
protein, and thus have a more dramatic eﬀect on its three-
dimensional structure than that of a single amino acid change.
If the predictions derived from our model here are con-
ﬁrmed, this could have implications in medical genetics and
human pathology. Mutations routinely assumed to be mis-
sense, nonsense or even silent could actually be causing disease
by aﬀecting the splicing pattern of the genes. Failure to recog-
nize this fact, could confound the understanding of the molec-
ular basis of disease, and could lead to a mis-assessment of the
severity of disease-causing mutations. Mutation analyses
exclusively performed at the genomic DNA level, therefore,
are not suﬃcient to correctly identify and characterize these
mutations. Analysis of mRNA splicing patterns when possible
in vivo and/or by employing reliable minigene splicing assays
in vitro, would be necessary for proper genetic diagnosis.
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